Providing Scholarships, Class Reunion Assistance, and More...

An oral anticoagulant being developed by Bristol-Myers Squibb Organization and Pfizer Inc.

Apixaban more advanced than enoxaparin in lowering venous thromboembolism altogether knee replacement surgery patients Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Organization and Pfizer Inc. , was more advanced than 40 mg once daily statistically enoxaparin in reducing the incidence of venous thromboembolism in patients going through elective total knee replacing surgery, according today in The Lancet to the ADVANCE-2 research results published. The study outcomes showed numerically lower rates of major and also clinically relevant non-main bleeding in patients treated with apixaban weighed against those treated with enoxaparin http://cialissverige.org/cialis-recensioner.html .

AD is a devastating age-related neurological disorder that impacts more than 4.5 million Americans and a lot more than 10 million people worldwide. Experts estimate that 22 million people all over the world and a lot more than 8 million People in america will be afflicted with this disease by 2025. ‘Aphios is usually developing APH-0703, a potent proteins kinase C modulator that activates the alpha-secretase pathway which can dramatically enhance the generation of soluble amyloid precursor proteins , diminishing plaques and cognitive deficits associated with Alzheimer’s Disease,’ explains Dr. Trevor P. Castor, President and CEO, Aphios Corporation. ‘We are developing novel formulations of APH-0703 predicated on Aphios’ proprietary hydrophobic-based formulation and patented SFS-PNS polymer nanospheres technology.